Recently, Zhang et al. reported their results from a phase 0 clinical trial of systemic IFNγ in two other immune cold tumors, synovial sarcoma and myxoid/round cell liposarcoma, where IFNγ resulted in increased MHC-I expression and significant T-cell infiltration with better tumor antigen presentation and less exhausted phenotypes of the TILs1. This evidence concerns the gene IFNG and neoplasm.